Rezende Marcussi Palata, Faria Fernanda Atoui, Beraldo Daniel Prado, Polido Julia, Belfort Rubens, Cabral Thiago
Department of Ophthalmology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
Clinica Oftalmo-Retina, Presidente Prudente, SP, Brazil.
Int J Retina Vitreous. 2025 Apr 22;11(1):51. doi: 10.1186/s40942-025-00672-7.
We used state-of-the-art high-resolution retinal imaging to explore the treatment (loading dose of aflibercept) of diabetic macular edema (DME) among treatment-naive patients. Swept-source (SS) OCT and OCT-Angiography (SS-OCTA) were performed, and a dichotomous analysis was conducted to compare responders and treatment-resistant patients (responsive and resistant). Furthermore, treatment responses were evaluated based on the subdivision of choroidal thickness.
This prospective, noncomparative, interventional case series study examined the following biomarkers: best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), avascular area of the superficial plexus (AASP), avascular area of the deep plexus (AADP), and vessel density (VD). Data from the baseline and 4-month examinations were compared.
Twenty-eight eyes from 25 patients were included. Significant improvements were observed in BCVA (0.7250 ± 0.23 to 0.3957 ± 0.21; p < 0.000), CMT µm (339.04 ± 66.19 to 265.21 ± 55.75; p < 0.000), CCT µm (221.71 ± 69.69 to 209.07 ± 70.92; p < 0.000), VD (17.90 ± 7.82 to 15.35 ± 5.80; p < 0.038), AASP µm (235,374 ± 91,299 to 157,326 ± 77,815; p < 0.000) and AADP µm (996,335 ± 1,000,047 to 362,161 ± 277,225; p < 0.000). Dichotomous analysis revealed that 15 patients were responsive (53.57%), and 13 resistant (46.43%). There were no significant differences between any of the pretreatment biomarkers. In the subdivision of choroidal thickness, which ranged from 211 to 270 µm (group 3), we found greater reductions in the CCT, AADP and CD. The choroidal thickness ranged from 181 to 210 µm (group 2): BCVA and AASP exhibited the greatest reductions.
BCVA, CMT, CCT, AASP, AADP and VD were improved after treatment. The pretreatment biomarkers did not predict treatment response between the responsive and resistant. Regarding choroidal stratification, values within the normal range of CCT showed the greatest reductions, indicating that these values may be more responsive to treatment. Notably, this is the first study to analyze biomarkers provided by SS OCT and OCTA, stratify the choroid, and perform a dichotomous analysis.
我们使用了最先进的高分辨率视网膜成像技术,来探索初治糖尿病性黄斑水肿(DME)患者的治疗方法(阿柏西普负荷剂量)。进行了扫频源(SS)光学相干断层扫描(OCT)和OCT血管造影(SS-OCTA),并进行了二分法分析,以比较反应者和治疗抵抗患者(反应性和抵抗性)。此外,根据脉络膜厚度细分评估治疗反应。
这项前瞻性、非对比性、介入性病例系列研究检测了以下生物标志物:最佳矫正视力(BCVA)、中心黄斑厚度(CMT)、中心脉络膜厚度(CCT)、浅表丛无血管区(AASP)、深部丛无血管区(AADP)和血管密度(VD)。比较了基线检查和4个月检查的数据。
纳入了25例患者的28只眼。观察到BCVA(从0.7250±0.23提高到0.3957±0.21;p<0.000)、CMT(μm,从339.04±66.19降至265.21±55.75;p<0.000)、CCT(μm,从221.71±69.69降至209.07±70.92;p<0.000)、VD(从17.90±7.82降至15.35±5.80;p<0.038)、AASP(μm,从235374±91299降至157326±77815;p<0.000)和AADP(μm,从996335±1000047降至362161±277225;p<0.000)有显著改善。二分法分析显示,15例患者有反应(53.57%),13例抵抗(46.43%)。任何治疗前生物标志物之间均无显著差异。在脉络膜厚度细分中,范围为211至270μm(第3组),我们发现CCT、AADP和CD的降低幅度更大。脉络膜厚度范围为181至210μm(第2组):BCVA和AASP的降低幅度最大。
治疗后BCVA、CMT、CCT、AASP、AADP和VD均有改善。治疗前生物标志物无法预测反应者和抵抗者之间的治疗反应。关于脉络膜分层,CCT正常范围内的值降低幅度最大,表明这些值可能对治疗更敏感。值得注意的是,这是第一项分析SS OCT和OCTA提供的生物标志物、对脉络膜进行分层并进行二分法分析的研究。